Skip to content
BillHelp
Menu
YOUR BILLHELP GUIDE

Diabetes Medication Denied by Insurance

What can I do if insurance denies a diabetes GLP-1?

A plan can deny Ozempic, Mounjaro, or another GLP-1 when the prescription is for type 2 diabetes. The notice may say approval was missing, that another drug must be tried first, that the drug is not on the formulary, or that the use is not medically necessary. A weight-loss prescription is a different denial. CMS says type 2 diabetes is a use that can be covered under Medicare Part D. A drug used for weight loss alone is not a Part D benefit. This page explains the appeal. It does not promise coverage.

Get help with my bill →
General U.S. guidance. Your plan documents and denial notice explain the process that applies to your case. Medicare, Medicaid, and other programs may use different rules. This is not medical or legal advice, and no result is guaranteed.

What should I read on a diabetes drug denial?

The label points below were checked on the FDA prescribing information for Ozempic and Mounjaro, and the Medicare points were checked on the CMS Part D page linked in this guide, on November 17, 2026. The denial notice controls the reason and the deadline.

Read the notice for the drug name, the strength, and the reason. A missing approval, step therapy, a formulary exclusion, and a medical-necessity decision are different problems. HealthCare.gov defines a formulary as the plan's drug list. HealthCare.gov says prior authorization is a decision about whether a service is medically necessary, and that it is not a promise of payment. If the notice says approval was missing, see a prior authorization denial. If another drug had to be tried first, see a step therapy denial. If the drug is not on the list, see a prescription drug the plan will not cover.

The FDA label for Ozempic, semaglutide injection, says it is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The same label also says it is indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. The FDA label for Mounjaro, tirzepatide injection, says it is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Those are the labeled uses. This page does not list every GLP-1 product. Use the name on your denial. Do not change or stop a medicine on your own. Ask the prescriber what to do if you may run out. If the denial is for an ADHD medicine rather than a drug for type 2 diabetes, see an ADHD medication denial.

References: HealthCare.gov: Preauthorization · HealthCare.gov: Formulary · FDA: Ozempic (semaglutide) prescribing information · FDA: Mounjaro (tirzepatide) prescribing information · HealthCare.gov: Internal appeals

How is this different from a weight-loss drug denial?

A prescription for weight loss alone is a different coverage question. Wegovy and Zepbound are different products from Ozempic and Mounjaro. That denial, including the separate Medicare program for some weight-loss prescriptions, is in a weight-loss medication denial. Do not describe a type 2 diabetes prescription as a weight-loss prescription, and do not ask anyone to enter a diagnosis the record does not support.

Ask the prescriber to name type 2 diabetes, when that is the condition being treated, on the prescription and on the prior authorization or exception request. For a Medicare Part D exception, 42 CFR 423.578 requires the prescriber's supporting statement to address the enrollee's disease or medical condition. The statement has to match the use. A request that describes the drug as for weight loss alone is the weight-loss question, not this one.

References: FDA: Ozempic (semaglutide) prescribing information · FDA: Mounjaro (tirzepatide) prescribing information · 42 CFR 423.578: Medicare Part D exceptions process

What if the plan requires another diabetes drug first?

A plan's written policy may require another diabetes drug, such as metformin, before it covers a GLP-1. That requirement is the plan's policy. This page does not say that every plan requires metformin, and it does not state a number of months. Ask for the policy the notice used. Your prescriber can respond to that policy, including a reason the required drug cannot be used. Do not ask anyone to record a trial that did not happen.

When a Part D plan uses step therapy, 42 CFR 423.578(b) treats that requirement as a formulary rule you can ask the plan to waive. The prescriber must state that the alternative was ineffective or is likely to be ineffective or to cause harm, under the tests in that section. For a health plan that provides essential health benefits, 45 CFR 156.122(c) is a process to request a clinically appropriate drug the plan does not otherwise cover. If the plan says the GLP-1 is not covered until the step is met, ask whether it is treating the drug as not covered under that section or as a limit on a listed drug. Use the process the notice names.

References: 42 CFR 423.578: Medicare Part D exceptions process · 45 CFR 156.122: Essential health benefit prescription drug exceptions · HealthCare.gov: Preauthorization

How does a formulary exception work?

45 CFR 156.122(c) applies to a health plan that provides essential health benefits. It is a process for you, your designee, or your prescriber to request a clinically appropriate drug the plan does not otherwise cover. HealthCare.gov describes prescription drugs as one of the essential health benefit categories. A plan that does not provide essential health benefits may not use this section. Ask the plan whether it provides those benefits.

For a standard exception, the plan must decide and notify you and the prescriber no later than 72 hours after it receives the request. For an expedited request, exigent circumstances exist when you are suffering from a health condition that may seriously jeopardize your life, health, or ability to regain maximum function, or when you are undergoing a current course of treatment using a non-formulary drug. The plan must decide an expedited request no later than 24 hours after it receives it. If the plan grants a standard exception, it must cover the drug for the duration of the prescription, including refills. If it grants an expedited exception, it must cover the drug for the duration of the exigency. If the plan denies the exception, you can ask for the external review in that same section, and the plan must decide that review no later than 72 hours for a standard request or 24 hours for an expedited request. Those hours are the plan's time to decide. They are not your deadline to file. The rest of the process is in a prescription drug the plan will not cover.

References: 45 CFR 156.122: Essential health benefit prescription drug exceptions · HealthCare.gov: Essential health benefits, including pediatric dental

What does Medicare Part D cover for these drugs?

CMS says type 2 diabetes is an indication eligible for Part D coverage, and that a person with that diagnosis is eligible to receive a GLP-1 through the Part D plan. CMS also says that diagnosis makes the person ineligible for the Medicare GLP-1 Bridge, even if the Part D plan does not cover a GLP-1 for that condition. The Bridge is a separate program for certain weight-management prescriptions. It is outside Part D. This page does not restate the Bridge's age, body-mass, or copay rules. Those rules are in a weight-loss medication denial.

42 CFR 423.100 leaves a drug out of the Part D definition when it is an agent used for anorexia, weight loss, or weight gain, through the exclusion in section 1927(d)(2) of the Social Security Act. A prescription whose only use is weight loss is not a Part D benefit. A type 2 diabetes use is not that exclusion. A plan can still leave a particular drug off its formulary. 42 CFR 423.566 says a decision not to provide or pay for a Part D drug, including because the drug is not on the formulary or is not medically necessary, is a coverage determination. You, your representative, or the prescriber may request it.

42 CFR 423.568 says that for a request for a drug benefit, the plan must notify you as expeditiously as your health requires and no later than 72 hours after it receives the request. For an exceptions request, that 72 hours runs from receipt of the prescriber's supporting statement. If the statement is not received by the end of 14 calendar days, the plan decides no later than 72 hours after those 14 days end. 42 CFR 423.570 says an expedited request does not include a request for payment of a Part D drug already furnished. If the plan grants an expedited request, 42 CFR 423.572 says it must decide as expeditiously as your health requires and no later than 24 hours after it receives the request, or after it receives the prescriber's supporting statement when the request is an exception. 42 CFR 423.578(f) says the prescriber's supporting statement does not, by itself, produce an approval. CMS says the plan must keep using its Part D exception process. The redetermination deadline is the date on your notice. The steps are in a prescription drug the plan will not cover.

References: CMS: Part D coverage of GLP-1 uses and the Medicare GLP-1 Bridge · 42 CFR 423.100: Part D drug definition · Social Security Act section 1927(d)(2): drugs that may be excluded, including weight loss · 42 CFR 423.566: Medicare Part D coverage determinations · 42 CFR 423.568: Medicare Part D coverage determination timeframes · 42 CFR 423.570: Expedited Medicare Part D coverage determinations · 42 CFR 423.572: Timeframes for expedited Medicare Part D coverage determinations · 42 CFR 423.578: Medicare Part D exceptions process · CMS: Medicare Part D exceptions, including step therapy

How do I appeal a diabetes drug denial?

Follow the notice. For a job-based plan, 29 CFR 2560.503-1 gives at least 180 days to appeal, and 45 CFR 147.136 applies that internal-appeal standard to non-grandfathered coverage. HealthCare.gov explains that appeal. See how to appeal a health insurance denial. If the dispute is whether the drug is medically necessary for type 2 diabetes, the notice may also offer external review. See how to request an external review. A denial that only says the plan does not cover weight-loss drugs does not answer a type 2 diabetes prescription. Ask the plan to point to the sentence it applied.

Send the prescriber's statement, the diagnosis in the record, and the labs the plan's policy asked for. Do not send a weight-loss prior authorization for a diabetes prescription. Nothing on this page promises that the plan or Medicare will cover the drug.

References: 29 CFR 2560.503-1: Claims procedure, including the 180-day appeal period · 45 CFR 147.136: Internal claims, appeals, and external review · HealthCare.gov: Internal appeals · HealthCare.gov: External review

What this page cannot promise

This is general information, not medical or legal advice. A plan can require a different diabetes drug first. A formulary exception can be denied. Part D does not cover a drug used for weight loss alone, and having type 2 diabetes does not place the prescription in the Medicare GLP-1 Bridge. An appeal can leave the denial in place. Nothing on this page promises that a plan or Medicare will cover Ozempic, Mounjaro, or another GLP-1, or cancel a bill.

Sources and further help

These sources provide general guidance. For a deadline or requirement that applies to you, follow your plan’s notice or the appropriate program’s current instructions.

Insurer websites may ask you to select your state or sign in. If a page will not open, use the member services number on your insurance card and ask for the current appeal instructions for your plan.

Report a broken link or suggest a correction.

← Explore all 141 guides